Healthcare personnel are at risk for occupational exposures to bloodborne pathogens. Primary prevention remains the first line of defense, but secondary prevention measures known to be effective should be implemented when percutaneous exposures occur. Hepatitis C virus (HCV) is a major infectious cause of liver-related morbidity and mortality. Chronic HCV treatment has changed dramatically, with many all-oral directly acting anti-HCV antiviral (DAA) regimens now available. Evidence for the use of DAAs as postexposure prophylaxis (PEP) after occupational exposures to HCV is summarized here.
INTRODUCTION
Healthcare personnel continue to be at risk of acquiring bloodborne pathogens such as HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) as a result of occupational exposures. The Centers for Disease Control and Prevention (CDC) estimates that more than 380 000 percutaneous-related injuries occur annually among hospital employees and approximately half of such exposures go unreported [1] [2] [3] . Primary prevention remains the most important strategy for averting occupational infection with bloodborne pathogens. When exposures do occur, secondary prevention with exposure-specific postexposure prophylaxis (PEP) should be offered to healthcare personnel when existing scientific evidence supports the use of PEP. Recommendations for HIV and HBV PEP have been recently updated, whereas similar guidelines for HCV exposures remain unchanged [4] [5] [6] . No vaccine, intravenous therapy, or other chemoprophylaxis is currently recommended for HCV PEP. However, the Food and Drug Administration (FDA) approval of several new antiviral directly acting anti-HCV antivirals (DAAs) has dramatically changed the landscape of chronic HCV management [7] . Treatment options now include all-oral regimens with shorter durations and fewer adverse effects than interferon (IFN)-based therapy [8] . In this context, we consider the role that these new agents may ultimately have in the management of HCV occupational exposures.
HCV is 3% with 130-150 million people estimated to have chronic infection and approximately 500 000 deaths per year attributed to HCV-related liver disease [9] . The most recent National Health and Nutrition Examination Survey (NHANES) estimate of the prevalence of HCV infection in the United States is 2.5-4.7 million [10 & ,11] . HCV is the leading cause of liver transplantation and, since 2007, has surpassed HIV as a cause of death in the United States [12, 13] .
The risk of developing HCV infection after a parenteral exposure is estimated at 1.9%. Although this risk is much lower when compared with similar exposures to HBV, the number of HCV patients accessing the US healthcare system appears to be increasing [14] . With no existing vaccine available, occupational exposure to HCV remains important.
HEPATITIS C LIFECYCLE AND PATHOGENESIS OF INFECTION
Understanding the HCV lifecycle has allowed development of drugs that have inhibitory actions targeted at various steps of the viral lifecycle. Antivirals currently on the market or in clinical development have two main targets of inhibition: HCV protein maturation (NS3-4a protease inhibitors) and HCV RNA synthesis [NS5a and nonnucleoside inhibitors, nucleoside/nucleotide analogues, and host target agents (HTAs)] [15] . HCV, a positive-stranded RNA virus lacking a latent form, replicates its genome directly into RNA using an error-prone RNA polymerase. The importance of the viral species heterogeneity resulting from such error was magnified by the selection of resistant viral variants that occurred during monotherapy with the first-generation HCV protease inhibitors, a class of DAAs with a low barrier to resistance. Selection of resistant viral variants does not usually occur when using drugs with a high barrier to resistance, but cross-resistance within a drug class can occur. Each of the currently approved DAAs has differing barriers to resistance and differing activity against each viral genotype. We now understand that successful antiviral regimens require a combination of drugs from different classes in order to increase the barrier to resistance and achieve lasting sustained virologic response (SVR).
MANAGEMENT OF HEPATITIS C OCCUPATIONAL EXPOSURE
Adherence to standard precautions remains the cornerstone of preventing occupational exposures [16] . Secondary prevention practices that have documented efficacy should be implemented when exposures occur after primary prevention fails. Any employee who sustains a workplace injury associated with risk for a bloodborne pathogen infection should receive immediate first aid. Further management recommendations such as cleansing the injury site, reporting exposures to occupational health, urgent evaluation of the exposure source for HIV, HBV, and HCV, and evaluation of the exposed healthcare worker for preexisting bloodborne pathogen infections, are unchanged [4] [5] [6] 17] .
Diagnostic testing recommendations specific to HCV exposure are also unchanged. Healthcare personnel who sustain occupational exposures to HCV should be tested for HCV antibody and for HCV RNA (by polymerase chain reaction). This initial testing should be performed within 48 h of exposure to document preexisting HCV infection [8] . Current US Public Health Service guidelines recommend repeat serological testing at 6 months [6] . Many US institutions have adopted a repeat testing frequency for both anti-HCV antibody and HCV RNA based upon either a 'preemptive' or 'watchful waiting' management strategy [18] . The first strategy, implementation of IFN therapy after detection of repeatedly positive HCV-RNA assays in the exposed healthcare worker, is based upon accumulated evidence that the treatment of acute HCV infection is more successful than chronic HCV. Proponents of 'watchful waiting', in which patients diagnosed with acute HCV are closely monitored for 3-4 months for persistent viremia before IFN is started, cite evidence that 20-40% of patients who develop acute HCV spontaneously clear their infections [19] . Both of these approaches aim to
KEY POINTS
Hepatitis C is a major global cause of liver-related morbidity and mortality and healthcare workers remain at risk for occupational exposures to this bloodborne pathogen.
Successful chronic HCV treatment requires the use of DAA regimens composed of a combination of drugs from different classes to increase the barrier to resistance and achieve lasting sustained virologic response.
No published data exist supporting the use of DAA or HTA regimens either for PEP or as primary therapy for acute HCV infection.
Effective HCV PEP regimens likely require the use of oral combination regimens that have pan-genotypic antiviral activity and a high barrier to resistance.
More evidence supporting the feasibility, duration, appropriate regimen, and cost-effectiveness is needed before HCV PEP could be recommended.
diagnose and treat acute infections before they progress to chronic HCV, a diagnosis with a poorer prognosis; however, the urgency of treating acute infection may be reduced with the notable success of oral DAAs in chronic infection. Current American Association for the Study of Liver Diseases guidelines recommend that if acute HCV infection is treated, the same genotype-specific regimens and duration as those approved for chronic infection should be used [8] .
HEPATITIS C POSTEXPOSURE PROPHYLAXIS
PEP for occupational exposures to bloodborne pathogens is treatment given to healthcare personnel in the time period immediately following exposure and has the goal of preventing infection with specific pathogens. This approach is distinguished from the 'preemptive' or 'watchful waiting' strategies which involve the treatment of a pathogen after infection has occurred.
The rationale for PEP administration after occupational exposures to HIV has been previously described [20] . Understanding the sequence of events of early HIV infection has provided data suggesting that early chemoprophylaxis may limit viral proliferation and dissemination within localized infected dendritic cells. Subsequent animal and human studies have demonstrated the efficacy of HIV PEP and it is now widely accepted practice in the United States [4] .
Less persuasive evidence exists for the use of PEP after occupational exposure to HCV. Previous case reports of IFN therapy given after needlestick injuries were either unsuccessful or unconvincing [21, 22] . A more recent pilot study examined the efficacy of 4 weeks of weekly peginterferon (PegIFN) administered to 44 of 51 enrolled healthcare personnel following percutaneous or mucous membrane exposures to HCV-positive sources [23] . No cases of HCV transmission occurred in any of the healthcare personnel, including 162 who did not enroll in the study. Because of the overall absence of HCV transmission, the authors concluded there was 'little evidence to support prophylaxis against hepatitis C in healthcare workers'. Given the relatively low infection rate associated with occupational exposures to HCV (i.e. approximately 2%) and the very high costs associated with the administration of DAAs, the strategy of monitoring for infection and then treating acute infection may be more cost-effective. In addition, the genotype-specific antiviral activity of DAAs makes PEP impractical when the source patient's genotype is not known.
One recent letter published in Hepatology raised many important questions about HCV PEP in the DAA era [24 & ]. As in the case for HIV, careful thought should be given to the pathogenesis of early vs. late HCV infection when considering the use of chemoprophylaxis. Clinical features such as age less than 40 years, female, and jaundice are associated with spontaneous viral clearance during acute infection [19] . However, the majority of people who have acute HCV infection are asymptomatic, making this stage of HCV infection difficult to identify. Nearly all of the existing evidence for DAA use is based upon experience in chronic HCV treatment; to our knowledge, no published trials or case reports describe the use of these agents either as PEP or as primary therapy for acute HCV infection. In this context, based upon our understanding of treatment during late infection, an effective HCV PEP regimen would presumably require a combination of at least two drug classes with the following requirements: 'pan-genotypic' activity against all HCV genotypes, a high barrier to resistance, easy tolerability, and treatment duration that is considerably shorter than the currently approved 12-to 24-week treatment regimens. Decreased adherence (either because of noncompliance or treatment duration) may result in resistant HCV viral variant selection. None of the current DAAs are approved specifically for PEP, but several approved or investigational agents may have a potential role in HCV PEP and are worthy of discussion (Table 1 ).
ORAL DIRECTLY ACTING ANTI-HCV ANTIVIRALS
Sofosbuvir, a nucleotide analogue that acts as a false substrate for the HCV RNA polymerase, is the only FDA-approved DAA with documented pangenotypic activity and a high barrier to resistance [15] . Sofosbuvir, in combination with ribavirin, is recommended as one option for treatment-naïve patients who have chronic infections caused by genotypes 2-4, and as an alternative regimen for those infected with genotypes 5 and 6 [8] . The treatment duration and recommendation to include IFN varies by genotype. High SVR rates were reported in genotype 1 patients when given with IFN for 12 weeks, but sofosbuvir/ribavirin (with or without IFN) is not recommended for use in genotype 1 because it is inferior to other recommended oral IFN-free regimens [8, 25] . The genotype-specific varying results of these trials and the lack of evidence for an entirely IFN-free regimen do not support the use of sofosbuvir/ribavirin as optimal HCV PEP chemoprophylaxis. Velpatasvir, an investigational pan-genotypic NS5A inhibitor, has recently been evaluated as a once-daily fixed-dose combination pill that also contains sofosbuvir. In January 2016, the FDA granted priority review to Gilead Sciences' New Drug Application for the use of sofosbuvir/velpatasvir in chronic HCV genotypes 1-6 [26] . Three recent studies have evaluated this combination in previously treated and untreated patients both with and without cirrhosis. ASTRAL-1 is a phase III, double-blind, placebo-controlled international trial comparing 12 weeks of sofosbuvir/velpatasvir to placebo in genotypes 1, 2, 4, 5, and 6 patients [27 && ]. Regardless of genotype, SVR12 rates were greater than 98% (99% in individuals with cirrhosis) in those receiving sofosbuvir/velpatasvir. ASTRAL-2 and ASTRAL-3 are phase III, randomized, open-label studies examining 12 weeks of daily sofosbuvir/ velpatasvir versus sofosbuvir/RBV for 12 weeks (genotype 2) or 24 weeks (genotype 3) [28
&&
]. Both studies demonstrated high SVR12 rates in patients treated with sofosbuvir/velpatasvir compared to sofosbuvir/RBV, although a greater difference was noted among genotype 3 patients (95 vs. 80%). In all three trials, patients receiving sofosbuvir/velpatasvir had rare virologic failure and experienced an overall low adverse event rate. Taken together, the results of the three ASTRAL studies suggest that sofosbuvir/ velpatasvir is a highly efficacious and well tolerated pan-genotypic DAA. Although the overall number of both genotype 5 and black patients were underrepresented in these studies, the combination of sofosbuvir/velpatasvir is promising. We await further investigational studies of this combination.
HOST TARGET AGENTS
Successful HCV replication depends upon interactions with human cellular components such as enzymes or small RNAs. HTAs block viral replication via inhibition of these components; because they target human structures, HTAs can exhibit both pan-genotypic antiviral activity and a high barrier to resistance [15] . Cyclophilin A is a proline isomerase whose interaction with NS5A is essential for HCV replication [29, 30] . Originally discovered as the target of the immunosuppressive drug cyclosporine, animal studies have demonstrated lower levels of HCV replication in cyclophilin A-deficient mice [29] . Three cyclophilin inhibitors currently in clinical development include alisporivir, SCY-635, and NIM811. Although early clinical trial data on alisporivir in genotypes 2 and 3 infections are promising, a trial in patients infected with genotype 1 was placed on partial clinical hold because of reports of pancreatitis [31 & ,32]. SCY-635, an oral cyclosporine A analog, stops HCV replication by blocking NS5A and cyclophilin A interactions [33] . A previous phase Ib study examined 15 days of SCY-635 dose escalation in 20 genotype 1 patients [34] . Serial IFN and HCV RNA serum levels revealed the greatest HCV RNA reduction in patients with IL28B genotype receiving SCY-635 300 mg thrice daily. Another study evaluated the addition of SCY-635 to PegIFN for 28 days in 10 treatment naïve genotype 1 patients without cirrhosis [35] . By week 24, 63% of patients who received SCY-635/PegIFN experienced undetectable HCV RNA; by contrast, none of the patients treated with PegIFN alone had a 2 log 10 HCV RNA decline. Similar HCV RNA declines were observed in a small safety and pharmacokinetic study of the addition of the cyclophilin inhibitor NIM811 to PegIFN [36] . Although the results from these three studies suggest that SCY-635 or NIM811 could restore human immune responses to IFN treatment, they likely have less relevance in the IFN-free regimen era. The role of cycophilin inhibitors in hepatitis C and other liver diseases has been recently reviewed [37] ; future studies could elucidate their role as an addition to oral treatment regimens [38] . At the current time, no evidence supports the use of either of these agents for chemoprophylaxis.
MicroRNAs are small noncoding RNAs involved in posttranscriptional gene expression regulation via binding site regions on messenger RNAs [39] . microRNA-122 is found in the human liver and stimulates HCV protein translation by direct interaction with the HCV genome, resulting in accelerated small ribosomal-HCV RNA binding [40] . Miravirsen is an injectable microRNA-122 inhibitor associated with HCV viral suppression in chimpanzee and human phase 1 studies [41] . A subsequent phase IIb study evaluating the safety and efficacy of 29 days of miravirsen given to 36 treatment-naïve genotype 1 patients demonstrated dose-dependent serum HCV RNA reductions [42] . Some animal studies have demonstrated that decreased levels of microRNAs could be associated with cancer. A recent phase IIa study in 16 chronic HCV patients treated with 4 weeks of miravirsen showed decreased microRNA-122 levels without significant reduction in other microRNA levels [43 & ]. While interesting, the use of an injectable drug for several weeks as HCV PEP is less desirable than oral options.
CONCLUSION
In summary, the treatment of HCV has rapidly evolved and the highly successful cure rates using IFN-free oral DAA combination regimens have tremendous potential to significantly reduce liver-related morbidity and mortality. From a public health standpoint, PEP could possibly help decrease the transmission of HCV and spare infected patients both the inconvenience and costs associated with additional weeks of treatment. However, data supporting the utility of PEP after HCV occupational exposures is lacking.
One reason why the DAAs may not have been used in the PEP setting is that these agents can effect a complete cure in most instances -even when longstanding, chronic HCV infection is detected. Conversely, PEP for occupational exposures to HIV may prevent an infection that cannot be subsequently cured with directly acting therapies. Because PEP use would treat approximately 100 HCV-exposed individuals for every two who become infected following occupational exposures, the 'watchful waiting' strategy may actually make most sense. The DAAs, as a group, are expensive, so this latter approach may be cost-effective as well.
Without doubt, clinical trials are needed to evaluate, in the postexposure setting, the feasibility, duration, appropriate regimens, and cost-effectiveness of PEP vs. monitoring for infection and treating acute infection when identified. At this point in time, insufficient evidence exists to support the use of DAAs or HTAs as HCV PEP. We await further data and/or the future development of oral drugs that possess a high barrier of resistance and broad activity against all HCV genotypes.
